Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Renal Autologous Cell Therapy™ (REACT) in Type 2 Diabetics With Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02836574
Recruitment Status : Active, not recruiting
First Posted : July 19, 2016
Last Update Posted : May 20, 2021
Sponsor:
Collaborator:
CTI Clinical Trial and Consulting Services
Information provided by (Responsible Party):
ProKidney, LLC

Brief Summary:

Study Part 1: Multi-center, prospective, open-label, randomized, double-arm, deferred treatment study whereby eligible subjects will be randomized 1:1 after kidney biopsy to receive up to 2 injections of REACT (made from expanded autologous selected renal cells) into the biopsied kidney beginning as soon as REACT can be prepared, or the same series of up to 2 injections given 6 months (+4 weeks) apart beginning 12 months after renal biopsy. Subjects will be followed through 24 months after the last injection.

Study Part 2: An open-label extension study in which eligible subjects will be followed for an additional 36 months of long-term follow-up.


Condition or disease Intervention/treatment Phase
Diabetic Chronic Kidney Disease Biological: Renal Autologous Cell Therapy (REACT) Phase 2

Detailed Description:

REACT is made from expanded autologous selected renal cells (SRC) obtained from each individual subject's kidney biopsy. To manufacture REACT, biopsy tissue from each enrolled subject will be sent to ProKidney LLC, in whose facilities renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin-based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site.

Based on preclinical data, the dose of REACT will be 3 x 106 cells/g estimated kidney weight (gKWest). Since the concentration of SRC per mL of REACT is 100 x 106 cells/mL, the dosing volume will be 3.0 mL for each 100 g of kidney weight.

Subjects will be randomized (1:1) to the Active Treatment Group or the Deferred Treatment Group following renal biopsy. Subjects in the Active Treatment Group will receive their first REACT injection as soon as the REACT product is manufactured and shipped to the clinical site. After 6 months (+4 weeks), a second injection will be given, as appropriate. In contrast, subjects in the "Deferred Treatment Group" will undergo a period of observation after renal biopsy. During this time, they will receive contemporaneous, standard-of-care therapy for CKD while undergoing follow-up evaluations every 3 months similar to subjects in the Active Treatment Group. After 12 months , subjects from the Deferred Treatment Group will receive a series of up to two REACT injections given 6 months (+4 weeks) apart, as appropriate. Consequently, the study design includes a randomized control group receiving standard-of-care treatment for the first 12 months and a randomized, active treatment group receiving up to two REACT injections and follow-up evaluations during the same period of time. In addition, each subject's baseline rate of renal decline, based on adequate historical, clinical data obtained 18 months prior to REACT injection, will serve as a comparator for monitoring the rate of progression of renal insufficiency over time.

The rate of progression of renal insufficiency for the Active Treatment Group (assessed via serial measurements of eGFR pre-randomization through 24 months after the last REACT injection) will be compared against that of the Deferred Treatment Group (ie, contemporaneous control group). In addition, each subject's baseline rate of eGFR decline (derived from adequate historical, clinical data) will be compared against the individual subject's rate of eGFR decline through 24 months following the final REACT treatment. The rate of progression of renal insufficiency from subjects (if any) who received a single REACT injection may be compared against that from subjects who received two REACT injections.

Subjects will complete the KDQOL survey, which is a kidney-specific measure of health-related quality of life (ie, Kidney Disease and Quality of Life™ [KDQOL™-36] Version 1) and the EQ-5D-5L. Scores from the Active Treatment Group will be compared against scores from the Deferred Treatment Group. Subjects from the Deferred Treatment Group will comprise the contemporaneous control group for the analysis of KDQOL scores. In addition, each subject's baseline scores will be compared against the individual subject's KDQOL scores obtained through 24 months after the last REACT injection. Additionally, KDQOL scores from subjects who received a single REACT injection may be compared against scores from subjects who received two injections.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 83 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Prospective, Randomized, Double-Arm, Deferred Treatment, Open Label, Repeat Dose, Safety and Efficacy Study of Renal Autologous Cell Therapy™ (REACT) in Subjects With Type 2 Diabetes and Chronic Kidney Disease
Study Start Date : September 2016
Estimated Primary Completion Date : May 2025
Estimated Study Completion Date : May 2028

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases

Arm Intervention/treatment
Experimental: Immediate Treatment
Renal Autologous Cell Therapy (REACT) immediate treatment - Patients who are randomized to receive their first treatment of 2 injections of REACT as soon as REACT product is made available.
Biological: Renal Autologous Cell Therapy (REACT)
Autologous selected renal cells (SRC).

Active Comparator: Delayed Treatment
Renal Autologous Cell Therapy (REACT) delayed treatment - Patients who are randomized to receive standard of care treatment for the first 12 months after REACT product is made available before receiving 2 injections of REACT.
Biological: Renal Autologous Cell Therapy (REACT)
Autologous selected renal cells (SRC).




Primary Outcome Measures :
  1. Change in Renal Function [ Time Frame: Through 24 months following last REACT injection ]
    eGFR at 24 months after last REACT injection


Secondary Outcome Measures :
  1. Treatment emergent adverse events [ Time Frame: Through 24 months following last REACT injection ]
    Treatment emergent adverse events, serial safety laboratory results



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria for Study Part 1:

  1. The subject is male or female, 30 to 80 years of age on the date of informed consent.
  2. The subject has an established diagnosis of T2DM.
  3. The subject has an established diagnosis of diabetic nephropathy as the underlying cause of renal disease.
  4. The subject has an established diagnosis of CKD not requiring renal dialysis, defined as having an eGFR between 20 and 50 mL/min/1.73m2 inclusive at the Screening Visit and prior to REACT injection.
  5. The subject has blood pressure less than 150/90 at the Screening Visit, prior to renal biopsy, and prior to REACT injection(s). At the time of the biopsy and injections, the subject's BP should not be significantly below the previously recorded stable pressure.
  6. The subject has stable blood pressure and is maintained on a stable anti-hypertensive medication regimen, if treatment for hypertension is necessary. If treatment includes an angiotensin-converting-enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB), that treatment must have been initiated at least 8 weeks prior to renal biopsy. Treatment must be stable during the 6-week period immediately prior to REACT injection. Stable treatment is defined as dose adjustment to no less than one half of the current dosage or to no more than 2 times the current dosage. Dose interruptions up to 7 days due to medical necessity are allowed.
  7. A minimum of 2 measurements of eGFR or sCr should be obtained at least 3 months apart prior to the Screening Visit or within the previous 18 months to define the rate of progression of CKD. The subject should have adequate, historical clinical data to provide a reasonable estimate of the rate of progression of CKD. The Medical Monitor may be consulted to ensure there is sufficient data.
  8. The subject is willing and able to refrain from NSAID consumption (including aspirin) as well as clopidogrel, prasugrel, or other platelet inhibitors during the period beginning 7 days before through 7 days after both the renal biopsy and REACT injection(s).
  9. The subject is willing and able to refrain from consumption of fish oil and platelet aggregation inhibitors, such as dipryridamole (ie, Persantine®), during the period beginning 7 days before through 7 days after both the renal biopsy and REACT injection(s).
  10. The subject is willing and able to cooperate with all aspects of the protocol.
  11. The subject is willing and able to provide signed informed consent.

Exclusion Criteria for Study Part 1:

  1. The subject has a history of type 1 diabetes mellitus.
  2. The subject has a history of renal transplantation.
  3. The subject has a serum HbA1c level greater than 10% at the Screening Visit.
  4. The subject has uncontrolled diabetes (defined as metabolically unstable by the Investigator).
  5. The subject has hemoglobin levels less than 9 g/dL prior to each REACT injection.
  6. The subject has abnormal coagulation status as measured by activated partial thromboplastin time (APTT), prothrombin time-international normalized ratio (PT-INR), and/or platelet count at the Screening Visit.
  7. The subject has a bleeding disorder(s) or is taking anticoagulants, such as Coumadin® (warfarin) or direct thrombin inhibitors that, in the judgment of the Investigator, would interfere with the performance of study procedures.
  8. The subject has small kidneys (average size less than 9 cm) or has only one kidney, as assessed by ultrasound and/or MRI prior to renal biopsy, unless earlier radiology reports (generated within 1 year of the Screening Visit) are made available to confirm kidney size and number.
  9. The subject has a known allergy or contraindication(s), or has experienced severe systemic reaction(s) to kanamycin or structurally similar aminoglycoside antibiotic(s)
  10. The subject has a history of anaphylactic or severe systemic reaction(s) or contraindication(s) to human blood products or materials of animal origin (eg, bovine, porcine).
  11. The subject is not a good candidate to undergo percutaneous REACT injection, in the judgment of the surgeon or physician who will perform the procedure. This includes individuals who are morbidly obese (defined as BMI greater than 45 kg/m2), have excessive fat surrounding the kidney, or who are otherwise at excessive risk for serious complications.
  12. The subject has a history of severe systemic reaction(s) or any contraindication to local anesthetics or sedatives.
  13. The subject has a clinically significant infection requiring parenteral antibiotics within 6 weeks of REACT injection.
  14. The subject has acute kidney injury or has experienced a rapid decline in renal function during the last 3 months prior to REACT injection.
  15. The subject has any of the following conditions prior to REACT injection: renal tumors, polycystic kidney disease, anatomic abnormalities that would interfere with the REACT injection procedure or evidence of a urinary tract infection.
  16. The subject has incapacitating cardiac and/or pulmonary disorders.
  17. The subject has a history of cancer within the past 3 years (excluding non-melanoma skin cancer and carcinoma in situ of the cervix).
  18. The subject has clinically significant hepatic disease (ALT or AST greater than 3-times the upper limit of normal) as assessed at the Screening Visit.
  19. The subject is positive for active infection with Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV), and/or Human Immunodeficiency Virus (HIV) as assessed at the Screening Visit.
  20. The subject has a history of active tuberculosis (TB) requiring treatment within the past 3 years.
  21. The subject is immunocompromised or is receiving immunosuppressive agents, including individuals treated for chronic glomerulonephritis within 3 months of REACT injection. Note: inhaled corticosteroids and chronic low-dose corticosteroids (less than or equal to 7.5 mg per day) are permitted as are brief pulsed corticosteroids for intermittent symptoms (eg, asthma).
  22. The subject has a life expectancy less than 2 years.
  23. The female subject is pregnant, lactating (breast feeding), or planning a pregnancy during the course of the study. Or, the female subject is of child-bearing potential and is not using a highly effective method(s) of birth control, including sexual abstinence. Or, the female subject is unwilling to continue using a highly-effective method of birth control throughout the duration of the study. Note: A highly effective method of birth control is defined as one that results in a low failure rate (ie, less than one percent per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine devices IUDs, sexual abstinence, or a vasectomized partner.
  24. The subject has a history of active alcohol and/or drug abuse that, in the judgment of the Investigator, would impair the subject's ability to comply with the protocol.
  25. The subject's health status would, in the judgment of the Investigator, be jeopardized by participating in the study.
  26. The subject has used an investigational product within 3 months prior to REACT injection without receiving written consent from the Medical Monitor.

Inclusion Criteria for Study Part 2:

  1. The subject is willing and able to provide signed informed consent.
  2. The subject was enrolled into Part 1 of the study and received at least one REACT injection.

Exclusion Criteria for Study Part 2:

1. The subject is currently receiving renal dialysis.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02836574


Locations
Show Show 17 study locations
Sponsors and Collaborators
ProKidney, LLC
CTI Clinical Trial and Consulting Services
Investigators
Layout table for investigator information
Study Director: Ashley Johns ProKidney, LLC
Study Director: Brian Johnston CTI
Layout table for additonal information
Responsible Party: ProKidney, LLC
ClinicalTrials.gov Identifier: NCT02836574    
Other Study ID Numbers: RMCL-002
First Posted: July 19, 2016    Key Record Dates
Last Update Posted: May 20, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency